SCCA

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Retrieved on: 
Thursday, March 7, 2024

ET

Key Points: 
  • ET
    SAN DIEGO and CALGARY, AB, March 7, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recent operational highlights and financial results for the fourth quarter and year ended December 31, 2023.
  • General and administrative expenses for the fourth quarter of 2023 were $4.2 million, compared to $3.7 million for the fourth quarter of 2022.
  • Research and development expenses for the fourth quarter of 2023 were $4.7 million, compared to $4.8 million for the fourth quarter of 2022.
  • The net loss for the fourth quarter of 2023 was $3.9 million, compared to a net loss of $8.6 million for the fourth quarter of 2022.

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Retrieved on: 
Thursday, February 15, 2024

According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."

Key Points: 
  • According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."
  • Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is developing pelareorep, a unique immunotherapy with the power to awaken the immune system and unlock its antitumor potential.
  • It is committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
  • Bristol-Myers Squibb and Fate Therapeutics are some of the other key patent filers in cancer immunotherapy."

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

Retrieved on: 
Wednesday, February 14, 2024

SAN DIEGO and CALGARY, Alberta, Feb. 14, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the expansion of enrollment for the anal cancer cohort of the GOBLET study evaluating pelareorep in combination with atezolizumab (Tecentriq®) in patients with second-line or later unresectable squamous cell carcinoma of the anal canal (SCCA). The study was expanded based on positive data from Stage 1 of the study, presented at the 2nd International Multidisciplinary Anal Cancer Conference (IMACC) in November 2023 (link to the PR, link to the poster).

Key Points: 
  • "These exciting clinical data, which exceed the Simon two-stage success criteria, provide strong support to expand the evaluation of pelareorep in patients with advanced anal cancer.
  • "We begin the Stage 2 expansion with substantial optimism for patients and the potential of pelareorep, especially considering the initial efficacy signal observed for pelareorep-based therapy in pancreatic cancer.
  • There is currently no established standard therapy for patients with anal carcinoma who have failed first-line treatment.
  • Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

Retrieved on: 
Wednesday, February 14, 2024

SAN DIEGO and CALGARY, Alberta, Feb. 14, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the expansion of enrollment for the anal cancer cohort of the GOBLET study evaluating pelareorep in combination with atezolizumab (Tecentriq®) in patients with second-line or later unresectable squamous cell carcinoma of the anal canal (SCCA). The study was expanded based on positive data from Stage 1 of the study, presented at the 2nd International Multidisciplinary Anal Cancer Conference (IMACC) in November 2023 (link to the PR, link to the poster).

Key Points: 
  • "These exciting clinical data, which exceed the Simon two-stage success criteria, provide strong support to expand the evaluation of pelareorep in patients with advanced anal cancer.
  • "We begin the Stage 2 expansion with substantial optimism for patients and the potential of pelareorep, especially considering the initial efficacy signal observed for pelareorep-based therapy in pancreatic cancer.
  • There is currently no established standard therapy for patients with anal carcinoma who have failed first-line treatment.
  • Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

Retrieved on: 
Thursday, January 4, 2024

Overview: "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy.

Key Points: 
  • Overview: "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy.
  • "We believe our cash balance and strong data, supported by our active business development program, position us well for 2024."
  • Together, these data provide a strong foundation to support advancing pelareorep into registrational-track studies, starting in 2024," continued Dr Coffey.
  • 2024 Outlook: Dr. Coffey concluded by saying, "Looking ahead to 2024, we expect to initiate the first Phase 3 study for pelareorep in pancreatic cancer.

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

Retrieved on: 
Thursday, January 4, 2024

Overview: "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy.

Key Points: 
  • Overview: "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy.
  • "We believe our cash balance and strong data, supported by our active business development program, position us well for 2024."
  • Together, these data provide a strong foundation to support advancing pelareorep into registrational-track studies, starting in 2024," continued Dr Coffey.
  • 2024 Outlook: Dr. Coffey concluded by saying, "Looking ahead to 2024, we expect to initiate the first Phase 3 study for pelareorep in pancreatic cancer.

Broad Arrow Announces Historic 1959 Porsche 718 RSK Spyder “Lucybelle III” as Highlight Consignment for Upcoming Amelia Island Auction this March 1-2, 2024

Retrieved on: 
Friday, December 22, 2023

The Porsche 718 RSK Spyder has an impressive period history having been sold new to American race car driver and former Le Mans winner Ed Hugus.

Key Points: 
  • The Porsche 718 RSK Spyder has an impressive period history having been sold new to American race car driver and former Le Mans winner Ed Hugus.
  • Broad Arrow will kickstart its 2023 calendar with the company’s inaugural Amelia Auction and debut as the official auction of The Amelia.
  • Set for March 1-2 at The Ritz-Carlton, Amelia Island, the Amelia Auction will feature exceptional collector cars ranging from pre-war classics to modern supercars.
  • Collectors interested in consigning their car(s) to this world-class event are invited to contact a Broad Arrow specialist via broadarrowauctions.com .

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

Retrieved on: 
Thursday, November 9, 2023

SAN DIEGO and CALGARY, Alberta, Nov. 9, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab in second-line patients with unresectable squamous cell carcinoma of the anal canal (SCCA) by Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial, in an oral presentation at the 2nd International Multidisciplinary Anal Cancer Conference (IMACC) 2023, taking place in Rome, Italy.

Key Points: 
  • "The positive interim data from the anal cancer cohort of the Phase 2 GOBLET study presented today at the IMACC meeting is very exciting for our company and the potential of pelareorep in gastrointestinal cancers.
  • These results met the pre-specified success criteria for the cohort and exceeded the results from historical controls in similar patient populations1-7," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics.
  • GOBLET Study SCCA Patient Overview:
    Patients in the SCCA cohort, presented at IMACC 2023, are undergoing second-line (2L) or later treatment with a combination of pelareorep and atezolizumab.
  • Two or more responses out of the first ten enrolled patients are required to satisfy the Simon two-stage success criteria.

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

Retrieved on: 
Thursday, November 9, 2023

SAN DIEGO and CALGARY, Alberta, Nov. 9, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab in second-line patients with unresectable squamous cell carcinoma of the anal canal (SCCA) by Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial, in an oral presentation at the 2nd International Multidisciplinary Anal Cancer Conference (IMACC) 2023, taking place in Rome, Italy.

Key Points: 
  • "The positive interim data from the anal cancer cohort of the Phase 2 GOBLET study presented today at the IMACC meeting is very exciting for our company and the potential of pelareorep in gastrointestinal cancers.
  • These results met the pre-specified success criteria for the cohort and exceeded the results from historical controls in similar patient populations1-7," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics.
  • GOBLET Study SCCA Patient Overview:
    Patients in the SCCA cohort, presented at IMACC 2023, are undergoing second-line (2L) or later treatment with a combination of pelareorep and atezolizumab.
  • Two or more responses out of the first ten enrolled patients are required to satisfy the Simon two-stage success criteria.

Southern California Contractors Association Names 2023 Award Winners

Retrieved on: 
Wednesday, November 1, 2023

The Southern California Contractors Association (SCCA), the region’s leading member-driven, nonprofit association for union contractors, has announced the winners of it 2023 President’s Gala awards program.

Key Points: 
  • The Southern California Contractors Association (SCCA), the region’s leading member-driven, nonprofit association for union contractors, has announced the winners of it 2023 President’s Gala awards program.
  • The program recognizes people and organizations that have made significant contributions to the industry and their communities while inspiring innovation in their respective fields.
  • SCCA’s “Industry Partner of the Year” will be presented to Rebuild SoCal for its work supporting statewide infrastructure projects and developing transportation education efforts in Southern California.
  • Finally, California State Assemblyman Tom Lackey will be honored with the “Ed Kalish Legislator of the Year” award for his unwavering support of the heavy civil construction community and advocacy for both businesses and labor alike.